



29th April 2016

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block,
Bandra Kurla Complex
Bandra (East), Mumbai 400051

Scrip Code: 500674

Scrip Code: SANOFI

Dear Sirs,

Re: Unaudited Financial Results for quarter ended 31st March 2016

We enclose herewith the Unaudited Financial Results of the Company for the quarter ended 31st March 2016 which were approved by the Board of Directors at its meeting held today.

As required by Regulation 33 (3) (c) (i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we also enclose herewith the Limited Review Report.

Thanking you,

Yours faithfully,

SANOFI INDIA LIMITED

A handwritten signature in black ink, appearing to read 'K. Subramani', written over a horizontal line.

K.SUBRAMANI
COMPANY SECRETARY

Encl: a/a

SANOFI INDIA LIMITED

Registered Office : Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.

Corporate Identity Number: L24239MH1956PLC009794

Tel no: (91-22) 28032000 Fax No: (91-22) 28032846

Website: www.sanofiindia.com Email: igrc.sil@sanofi.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2016

Rs. Million

PART I Particulars	Quarter ended 31.03.2016	Quarter ended 31.12.2015 (Audited) Ref Note 4	Quarter ended 31.03.2015	Year ended 31.12.2015
	(Unaudited)		(Unaudited)	(Audited)
1. Income from Operations				
(a) Net Sales (net of excise duty)	5,063	5,224	4,598	20,493
(b) Other Operating Income	381	463	291	1,438
Total income from Operations (net)	5,444	5,687	4,889	21,931
2 Expenditure				
(a) Cost of Materials Consumed	1,854	1,416	1,416	6,339
(b) Purchase of stock in trade	1,239	1,074	1,252	3,413
(c) Changes in inventories of finished goods, work in progress and stock in trade	(466)	43	(269)	364
(d) Employee benefits expense	836	945	787	3,333
(e) Depreciation and amortisation expense	301	296	259	1,130
(f) Other expenses	890	1,080	874	3,891
Total Expenses	4,454	4,854	4,319	18,470
3 Profit from Operations before other income, finance costs and exceptional items (1-2)	990	833	570	3,461
4 Other Income	256	126	194	514
5 Profit from Operations before finance costs and exceptional items (3+4)	1,246	959	764	3,975
6 Finance costs	1	1	1	4
7 Profit before tax and Exceptional Items (5-6)	1,245	958	763	3,971
8 Tax expense	439	433	279	1,594
9 Net Profit for the period before Exceptional Items (7-8)	806	525	484	2,377
10 Exceptional item (net of tax)	-	677	161	838
11 Net Profit for the period after Exceptional Items (9+10)	806	1,202	645	3,215
12 Paid-up equity share capital (Face Value of Rs. 10 per share)	230	230	230	230
13 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	16,004
14 Earnings Per Share (EPS) before Exceptional Items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	35.04	22.67	21.04	103.18
15 Earnings Per Share (EPS) after Exceptional Items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	35.04	52.09	28.04	139.59

PART II

Particulars				
A. PARTICULARS OF SHAREHOLDING				
1 Public Shareholding				
- Number of Shares	9,121,035	9,121,035	9,121,035	9,121,035
- Percentage of Shareholding	39.60%	39.60%	39.60%	39.60%
2 Promoters and Promoter group Shareholding				
a) Pledged/Encumbered				
- Number of shares	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total share capital of the company)	NIL	NIL	NIL	NIL
b) Non-encumbered				
- Number of shares	13,909,587	13,909,587	13,909,587	13,909,587
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of total share capital of the company)	60.40%	60.40%	60.40%	60.40%

Particulars	3 Months ended March 31, 2016
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	6
Disposed of during the quarter	6
Remaining unresolved at the end of the quarter	NIL

[Handwritten Signature]

SIGNED FOR IDENTIFICATION
BY *[Signature]*
S B B C & CO LLP
MUMBAI

Notes:

1. The above Results were approved by the Board of Directors of the Company at its Meeting held on April 29, 2016.
2. In accordance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended March 31, 2016.
3. The Board of Directors had, at its Meeting held on February 4, 2016, recommended (i) Final dividend of Rs. 25 per Equity share of Rs.10 for the year ended December 31, 2015; (ii) a Special One-time dividend of Rs.14 per Equity Share of Rs.10 (arising from profit from sale of commercial premises) ; and (iii) a Special One-time Diamond Jubilee Dividend of Rs.8 per Equity Share of Rs.10 .The said total dividend of Rs.47 per Equity Share of Rs.10, if declared at the Annual General Meeting to be held on April 29, 2016, will be paid on May 9, 2016.
4. The figures for the quarter ended December 31, 2015 are the balancing figures between audited figures in respect of the full financial year ended December 31, 2015 and the unaudited published year-to-date figures upto September 30, 2015, which was subject to limited review, being the date of the end of the third quarter of the said financial year.
5. The Company has a single business segment namely 'Pharmaceutical Business'.
6. The figures for the previous periods have been re-grouped, wherever necessary.
7. Following the amendment of Schedule I of Drugs (Prices Control) Order 2013, the National Pharmaceutical Pricing Authority (NPPA) has notified the ceiling prices of certain products of the Company with effect from April 2016. Consequently, the Company has reduced the prices of such products. This will have an adverse impact on the sales and profitability of the Company.



SANOFI INDIA LIMITED

**SHAILESH AYYANGAR
MANAGING DIRECTOR**


April 29, 2016

Limited Review Report

**Review Report to
The Board of Directors
Sanofi India Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Sanofi India Limited ('the Company') for the quarter and three months ended March 31, 2016 (the "Statement"). This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP
ICAI Firm registration number: 324982E/E300003
Chartered Accountants


per **Vijay Maniar**
Partner
Membership No.: 36738



Place: Mumbai
Date: April 29, 2016